DAPI (in blue), pan-cytokeratin (CK) (in green) and EpCAM (in red) staining of cells isolated using the ClearCell® FX System. CTCs are shown to be CK + and EpCAM...Read More
ClearCell® FX1 System
Driven by CTChip® FR
The ClearCell® FX1 System, driven by the CTChip® FR, is one of the world's first automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in a relatively short time.
Combined with the high levels of purity, the CTCs are enriched in suspension, which allows for easy integration with downstream molecular analyses and diagnostic assays. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.
The microfluidic biochip captures CTCs based on inertial characteristics such as size and deformability, relative to other blood components, by using Dean Flow Fractionation (DFF). Through the DFF process, the cells are focused within the microfluidic channels of the CTChip® FR, with larger cells along the inner wall and the smaller cells away from it.
This label-free approach ensures effective, continuous and quick separation while retaining cell viability thus lending itself to a myriad of downstream applications.
NewsGenomeWeb Feature: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop CTC CoRE in the U.S. PR Newswire: John Wayne Cancer Institute, and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S. BioSpectrum: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership
20-22 APRIL 2017 | San Francisco, USA | Plenary SessionRead more